FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 251 filers reported holding FATE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $54,971 | -45.4% | 9,644 | -3.3% | 0.00% | -50.0% |
| Q4 2022 | $100,597 | -86.3% | 9,970 | -69.6% | 0.00% | -86.7% |
| Q3 2022 | $735,000 | -11.7% | 32,813 | -2.2% | 0.02% | -6.2% |
| Q2 2022 | $832,000 | -46.0% | 33,559 | -15.6% | 0.02% | -33.3% |
| Q1 2022 | $1,541,000 | -38.8% | 39,742 | -7.7% | 0.02% | -33.3% |
| Q4 2021 | $2,519,000 | +2.7% | 43,046 | +4.1% | 0.04% | -2.7% |
| Q3 2021 | $2,452,000 | -20.3% | 41,368 | +16.6% | 0.04% | -17.8% |
| Q2 2021 | $3,078,000 | +25.8% | 35,466 | +19.5% | 0.04% | +18.4% |
| Q1 2021 | $2,446,000 | +53.4% | 29,670 | +69.1% | 0.04% | +46.2% |
| Q4 2020 | $1,595,000 | +520.6% | 17,542 | +172.7% | 0.03% | +420.0% |
| Q3 2020 | $257,000 | +117.8% | 6,433 | +86.3% | 0.01% | +150.0% |
| Q2 2020 | $118,000 | – | 3,453 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |